Conditions We Treat
We provide relief from chronic neuropathic & oncologic pain.
These conditions may include:
Low back pain
Post-surgical neuropathic pain
Reflex sympathetic dystrophy (RSD)
Complex regional pain syndrome (CRPS)
Postherpetic neuralgia (PHN)
Phantom limb syndrome
Cancer induced pain
Chemotherapy-induced peripheral neuropathy (CIPN)
If you have been diagnosed with any of the above conditions, or if you are suffering from a constant burning or deep aching pain, numbness or pins and needles sensation Calmare Therapy may be able to help.
Scrambler Therapy General Information
Fifty-two patients were randomized. The mean VAS pain score before treatment was 8.1 points (control) and 8.0 points (Scrambler). At one month, the mean VAS score was reduced from 8.1 to 5.8 (28%) in the control group, and from 8 to 0.7 points (91%) in the Scrambler group (P < 0.0001). At two and three months, the mean pain scores in the control group were 5.7 and 5.9 points, respectively, and 1.4 and 2 points in the Scrambler group, respectively (P < 0.0001). More relapses were seen in polyradicular pain than monoradicular pain, but retreatment and maintenance therapy gave relief. No adverse effects were observed. In this pilot randomized trial, Scrambler therapy appeared to relieve chronic neuropathic pain better than guideline-based drug management.
Two hundred nineteen patients were treated for chronic pain of different nature with mean values of 6.44 (± 2.11) at T0, 3.22 (± 2.20) at T2, and 3.19 (± 2.34) at T4. A reduction in the symptomatology from T0 to T2 was maintained throughout T4 (P value < .0001). Of the 219 patients treated with ST, 83 (37.9%) had cancer pain and 136 (62.1%) had non-cancer pain. No adverse events were reported. Future research should focus on individual response, retreatment, and maintenance therapy. The data showed a statistically significant impact of ST, which was maintained during follow-up, on patients suffering from chronic pain of different nature.
A neuropathic or mixed neuropathic-nociceptive pain condition was associated with a positive treatment outcome. Investigators should consider these findings when developing selection criteria in clinical trials designed to determine the efficacy of Calmare therapy.
All the patients were suffering from chronic pain with a mean pain NRS of 7.41 (SD 2.06) before treatment. Main causes of chronic pain: post herpetic neuralgia 18.40 %, chronic low back pain (LBP) 37.31%, polyneuropathy 10.94%, and peripheral neuropathy 14.42 %. The remaining 18.93 % included chronic pain due to other causes. The difference between pre-treatment NRS 7.41 (SD 2.06) and post-treatment 1.60 (SD 2.22) was statistically significant (P< 0.0001). The mean number of sessions per patient was 10, but 39 had complete absence of pain sooner and used fewer sessions. Only 7 patients stopped treatment due to lack of results, and 2 for personal reasons not ascribable to the treatment. Stimulation pain score of 0 during treatment, and not just pain reduction, predicts long term effectiveness, so this must be pursued by optimizing electrode positioning and correct fine-tuning of stimulation intensity. Scrambler Therapy is an efficient and safe alternative for several different types of refractory chronic neuropathic pain, with a very rare possibility of adverse events.
Cancer Pain and Chemotherapy-Induced Peripheral Neuropathy
Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy Supportive Care in Cancer
Thirty-seven patients were enrolled. Twenty-five patients were treated primarily on their lower extremities while 12 were treated primarily on their upper extremities. There was a 53 % reduction in pain score from baseline to day 10; a 44 % reduction in tingling; and a 37 % reduction in numbness. Benefit appeared to last throughout 10 weeks of follow-up. There were no substantial adverse events. Preliminary data support that Scrambler therapy may be effective for the treatment of CIPN: a prospective placebo-controlled clinical trial should be performed.
Scrambler Therapy for Patients with Cancer Pain. The Korean Journal of Pain
The authors were able to obtain a satisfactory effect by administering scrambler therapy in patients with cancerous pain caused by bone metastasis of cancer cells and in whom pain control through palliative treatment methods had proven difficult. Scrambler therapy is non-invasive, has no complications, causes minimal discomfort during treatment, and is similar or superior to other existing treatments in effect and duration. However, there is insufficient comparative research regarding the effect of scrambler therapy for various types of pain. Therefore, validation is needed. More research is also necessary regarding the factors that influence response to the treatment.
A Trial of Scrambler Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy Journal of Pain & Palliative Care Pharmacotherapy
No adverse effects were observed. In this single arm trial, Scrambler therapy appeared to relieve cancer-associated chronic neuropathic pain both acutely and chronically, and provided sustained improvements in many indicators of quality of life.
An 11-year-old female patient was suffering from left groin and medial thigh pain after irradiation to the knee. The girl was diagnosed with precursor B-cell lymphoblastic leukemia 2 years ago. Extramedullary relapse of leukemia developed 1 month ago and pain had started. She was treated with oral medications, but she was continuously complaining of severe pain. During treatment, the NRS score decreased from 8/10 to 3/10 after the first session. Subsequent sessions were followed by marked improvement of pain: after 3 treatment sessions, NRS score was 0/10. Following pain reduction, drugs were progressively reduced and then prescribed at need. No other treatment sessions were performed. No adverse events were observed. We evaluated her pain control by phone. Pain intensity was investigated 1 and 4 weeks after completion of treatment: the patient referred to no pain.
Chronic post-mastectomy pain (cPMP), including post-lumpectomy pain, is common with no established ways of treatment. We treated three consecutive patients referred with cPMP with scrambler therapy (ST), a non-invasive electrical neurocutaneous stimulation. Treatment was given across the area of pain following the dermatomes for 45 minutes daily, for several consecutive days until relief, and then was repeated as needed. The ST MC5A device synthesizes 16 different waveforms that resemble action potentials, delivered to the surface receptors of the c-fibers, to send "non-pain" information along the damaged pathways to reduce central sensitization. All three had marked (over 75%) and sustained (months) reduction of allodynia, hyperalgesia, and pain. All reported marked improvements in their quality of life and normal function. One woman was able to stop chronic opioid use. No side effects were observed. Scrambler therapy is a promising way to relieve cancer and other types of neuropathic pain, and may be helpful in cPMP. Further prospective trials are warranted.
Artificial neurons in oncological pain: the potential of Scrambler Therapy to modify a biological information. International Congress Series
The entire sample responded positively to the treatment throughout the statistical reference period and continued with unchanged effectiveness until the end point was reached. Seventy-two percent of the patients suspended treatment with painkillers during the first applications, while the remaining 28% considerably reduced the dose they were taking prior to Scrambler Therapy. No undesirable side effects emerged and compliance proved to be optimal.
Complex Regional Pain Syndrome
We report the response to ST in four patients with CRPS referred to the Pain Center of Bambino Gesù Children's Hospital. The patients previously did not respond to conventional and nonconventional medical treatments. The treatment with ST was found effective in all four of our patients; they obtained pain relief for long periods and an improvement in their quality of life. We observed a progressive improvement with complete disappearance of neuropathic pain. Patients also reported a muscle strength increase that allowed them to resume normal daily activities.
Chronic Low Back Pain
Effects of scrambler therapy on pain and depression of patients with chronic low back pain: case study. Journal of Physical Therapy Science.
This study was designed to investigate the effect of scrambler therapy on the pain and depression of patients with chronic low back pain. [Subject and Methods] Applied scrambler therapy to a 52 year-old man who was diagnosed with chronic low back pain, for 40 minutes once a day during the 10-day execution. Pain and depression were measured using the visual analogue scale and the Beck Depression Inventory. [Results] According to the measurement results, pain and depression decreased after ten sessions of scramble therapy. Scrambler therapy shows positive effects on pain and depression of patients with chronic low back pain.
Clinical Experiences on the Effect of Scrambler Therapy for Patients with Postherpetic Neuralgia. The Korean Journal of Pain
In conclusion, through this report, we show that Scrambler Therapy can be a good option for the treatment of patients with PHN, who respond poorly to previous conventional treatments or have a fear of receiving other invasive treatments due to one’s own comorbidity. However, we suggest that more extensive investigations with a large number of patients are necessary to provide well established guidelines for Scrambler Therapy of PHN.
The aim of this study was to analyze the effect of pain scrambler therapy on antineuralgic pain and quality of life after shingles. [Subjects and Methods] Daily pain scrambler therapy was administered to antineuralgic patients for 10 days, with each session lasting approximately 40 minutes. Pain was measured using the visual analog scale, and quality of life was assessed with the short form 36-item (SF-36). [Results] After10 sessions of pain scrambler therapy, pain had significantly reduced compared to that experienced prior to treatment. The quality of life had also improved following completion of 10 treatment sessions. [Conclusion] Pain scrambler therapy decreased patients’ post-shingles antineuralgic pain and improved quality of life.
Treatment of human immunodeficiency virus-related peripheral neuropathy with Scrambler Therapy: a case report. International Journal of STD & AIDS
We treated a 52-year-old man who had severe disabling classic peripheral neuropathy since 1998 with Scrambler Therapy (Calmare), an FDA-cleared peripheral non-invasive neuromodulation device. His pain rapidly improved, as did his motor and sensory function, with just four 45-min treatments, and he was able to come off opioids for the first time in years. When his pain returned six months later, only two treatments were needed to resolve it. This represents the first published use of this novel, inexpensive, and non-invasive pain modality in HIV peripheral neuropathy, and should engender further trials.
For all 16 patients, NRS showed mean values of 6.75 ± 1.13 before therapy, 5.06 ± 1.53 after 5 sessions, and 4.13 ± 1.45 after 10 sessions. The NRS values before therapy and after 10 sessions were significantly different (p < 0.05). Pruritus frequency, severity, and consequences scores on the Leuven Itch Scale after Scrambler therapy were also significantly different (p < 0.05). Duration, degree, direction, and disability scores on the 5-D Itch Scale were also significantly different (p < 0.05). Scrambler therapy is a non-invasive, non-medicinal modality that significantly reduced burn-associated pruritus. Scrambler therapy should be considered as a treatment option for burn survivors with severe pruritus.
Severe scar pain is individually uncommon but collectively common and is highly distressing without uniformly effective treatments. Scrambler Therapy gave quick and sustained relief for months with just one or two sessions, and should be studied prospectively in larger multi-site trials.